Diabetes drug trial needs to widen participants to understand full impact of drugs - Science Daily

Diabetes drug trial needs to widen participants to understand full impact of drugs Science Daily Examining data from over 60,000 patients with type 2 diabetes, researchers from the University of Surrey discovered that the highly-publicised cardiovascular benefits of the popular diabetes drug empagliflozin cannot be applied to the vast majority of ...